November 8, 2017
Very High Volatility and Mixed Performance
The key statistic from analysis of the 9-month share price performance is that 52 of 115 companies (45%) had share price changes greater than 40%.
For most of my personal biotech investing, I look for potential doubles in the next 12 months – it is always nice to see that there are opportunities for those returns. Volatility is not necessarily bad for this investment style as it can help share prices bounce off bottoms, or over-react to announcements, which are both positive and negative.
An investor should always ask ‘how does the average share price change compare with some benchmarks in Q2?’
U.S. markets will sometimes drag the Canadian indices along for the ride, up or down. Volatility of the S&P 500 as measured by the VIX is at its lowest point of 2017 and the U.S. markets have churned to all-time highs through much of 2017.
How does all this affect the Canadian healthcare sector? The Russell 2000 is viewed as the U.S. small cap index. On May 12, 2017, the lowest and median market caps of the companies in this index were U.S. $144 M and U.S. $784 M, respectively. Most of the Canadian healthcare companies in our analysis are microcaps and, unless U.S. trends drive investors to the sidelines, there is no correlation between their performance and U.S. market performance.
The development stage Canadian healthcare companies generally rely upon institutional investors for funding and retail investors for liquidity between deals. The share price changes which I have summarized and assessed each quarter reflect retail trading, general sector sentiment, broad stock market trends and, most importantly from my perspective, corporate events and performance.
In the next blog post, I will assess the Q3 and 9-month 2017 share price performance of the Tier 1 Canadian healthcare companies.
[The author and his immediate family members may have long or short positions in the shares of some companies mentioned in or assessed during the preparation of this blog. Past share price performance may not be an indicator of future share price performance. This blog does not consider the investment objectives, financial situation or particular needs of any particular person. Investors should obtain professional advice based on their own individual circumstances before making an investment decision.]
As with all our posts, please see our full legal disclaimer
<
>
Canada in Science - November 9, 2018
America's Midwestern Gem: How Chicago is Building the Next Biomedical Research Hub
Canada in Science - September 7, 2018
Q2 2018 Share Price Performance
Canada in Science - August 3, 2018
Canada in Science - July 6, 2018
Greenbrook TMS Announces Closing of Private Placement Totaling USD $20,000,000
Canada in Science - June 7, 2018
CannTrust™ Announces Closing of $100,395,000 Bought Deal
Bloom Burton & Co. Welcomes Michael J. Brown, CFA® as Portfolio Manager and Chief Executive Officer of its Asset Management Affiliate, Bloom Burton Investment Group.
Q1 2018 Share Price Performance
From Motor City to Health Innovation City? Detroit's Unexpected Comeback
Kneat Announces Closing of $6.185 Million Brokered Private Placement
Canada in Science - April 6, 2018
Sunniva Inc. Closes $27.8 Million Bought Deal Public Offering
Immunovaccine Announces Closing of CAD$14,375,000 Bought Deal Offering with Over-Allotment Option Exercised in Full
Canada in Science - March 2, 2018
Big Pharma's Drug War: Innovative vs. Generic and Biosimilar Drugs
Bloom Burton & Co. Announces the 2018 Bloom Burton Award Gala
Canada in Science - Feb 2, 2018
Plasma for Profit: The Changing Landscape of Blood Donation
Q4 & Annual 2017 Share Price Performance - Part 3
Q4 & Annual 2017 Share Price Performance - Part 2
ESSA Completes US$26 Million Equity Offering
Paul Lammers, M.D., M.Sc. Joins Triumvira as President and Chief Executive Officer
Q4 Share Price Performance in 2017 - Part 1
BELLUS Health Closes $20M Common Share Financing
Canada in Science - December 1, 2017
Avivagen Announces Closing of Private Placement Totaling $4,000,000
CannTrust™ Announces Closing of $20,000,000 Bought Deal
The Emergence of the HIV/AIDS Epidemic and How it Affected the Human Plasma Industry
Q3 Share Price Performance in 2017 - Part 3
Q3 Share Price Performance in 2017 - Part 2
Q3 Share Price Performance in 2017 - Part 1
Canada in Science - November 3, 2017
Acquisitions in the Life Sciences Start-Up Space: A Principal-Agent Problem in the Making
Appili Therapeutics Receives FDA and Health Canada Clearance to Begin Clinical Trials on ATI-1501